LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.21 -3.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.16

Max

4.33

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Aktsiakasum

-0

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+48.1% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-848K

560M

Eelmine avamishind

7.87

Eelmine sulgemishind

4.21

Uudiste sentiment

By Acuity

50%

50%

146 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 20:38 UTC

Tulu

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10. märts 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10. märts 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10. märts 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10. märts 2026, 23:35 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10. märts 2026, 23:06 UTC

Tulu

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10. märts 2026, 22:51 UTC

Uudisväärsed sündmused

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10. märts 2026, 21:21 UTC

Tulu

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10. märts 2026, 21:15 UTC

Tulu

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10. märts 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10. märts 2026, 21:14 UTC

Tulu

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10. märts 2026, 21:13 UTC

Tulu

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q Rev $597.3M >FNV

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q EPS $1.90

10. märts 2026, 20:57 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

10. märts 2026, 20:44 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:34 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

10. märts 2026, 20:34 UTC

Market Talk
Tulu

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10. märts 2026, 20:23 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:16 UTC

Tulu

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10. märts 2026, 20:14 UTC

Tulu

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10. märts 2026, 20:14 UTC

Tulu

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10. märts 2026, 20:13 UTC

Tulu

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10. märts 2026, 20:12 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

48.1% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  48.1%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

146 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat